


---

# **DEPARTMENT OF PHARMACY QUARTERLY REPORT**

**APRIL 26<sup>TH</sup> 2021**

**DOMINIC MELLETTE PHARM D  
CHIEF PHARMACY OFFICER**



**OUR DRIVE-THRU  
LANE HAS BEEN  
PAVED!**



**A NEW PHARMACY  
DISPENSING  
ROBOT HAS BEEN  
INSTALLED AT  
CCPNW**



## **WE ARE NOW LIVE WITH PAR80**

- Will allow us to qualify and capture referral Rxs filled at contract pharmacies
- Rxs are qualified based on data feeds we send to Par80.
  - \*Par80 has no actual access to our EHR- added security/peace of mind
- Potential to add significant amount of contract pharmacy revenue

## **340B EPIPEN/INSULIN REGULATION HAS BEEN DELAYED**

- In late March BPHC announced reg. will be delayed until 7/20/21
- Justification for extension:
  - Consistent with Biden administration's regulatory freeze
  - Further delay appropriate given the critical role that CHCs have been assigned since January-testing and vaccinating hard to reach populations.

## CONTINUED ASSAULT ON CONTRACT PHARMACY

- Last December HRSA finally released a 340b ADR (administrative dispute resolution) process
- ADR board would help resolve:
  1. Covered entity claims that they were overcharged
  2. Claims by mfgs that covered entity has either violated duplicate discount, or diversion rules
- Lilly sued HHS over ADR process saying it was invalid and federal judge agreed
- \*Now once again HHS has gone through the appropriate steps in implementing ADR process- **Good news!**

**HUDSON  
HEADWATERS  
EXTERNAL AUDIT  
CONDUCTED ON  
MARCH 24<sup>TH</sup>.**

- Yearly audit we schedule to endure 340b program compliance
- Audit went well, HH did have some concerns they feel we should address:
  - Suggested more oversight on contract pharmacy
  - Recommended some additions to our policies and procedures
  - Slight address changes with OPAIS and EHB.



ANY  
QUESTIONS